- Brand names:
- Pharmaceutical Company:
- Condition/Indication:
- Meeting Date: July 2018
- Public Summary Document (PSD) July 2018 PBAC Meeting - PDF
- Public Summary Document (PSD) July 2018 PBAC Meeting - Word
Nivolumab and ipilimumab (renal cell carcinoma) – July 2018
Nivolumab and ipilimumab (renal cell carcinoma): Nivolumab: Injection concentrate for I.V. infusion
Last updated
15 March 2019